Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 pediatric study of BAX326 in previously treated patients with hemophilia B
2011-002437-19Phase 2Completed
- Sponsor
- Baxter International Inc.
- Start
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Baxter International Inc. Primary endpoint: Treatment-related adverse events. Started Sep 2011; status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2011-002437-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002437-19.